JP2023515771A5 - - Google Patents

Info

Publication number
JP2023515771A5
JP2023515771A5 JP2022547943A JP2022547943A JP2023515771A5 JP 2023515771 A5 JP2023515771 A5 JP 2023515771A5 JP 2022547943 A JP2022547943 A JP 2022547943A JP 2022547943 A JP2022547943 A JP 2022547943A JP 2023515771 A5 JP2023515771 A5 JP 2023515771A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
scleroderma
composition according
fibrosis
accumulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022547943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/016666 external-priority patent/WO2021158823A1/en
Publication of JP2023515771A publication Critical patent/JP2023515771A/ja
Publication of JP2023515771A5 publication Critical patent/JP2023515771A5/ja
Pending legal-status Critical Current

Links

JP2022547943A 2020-02-04 2021-02-04 強皮症および関連する疾病の処置のための方法 Pending JP2023515771A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062970063P 2020-02-04 2020-02-04
US62/970,063 2020-02-04
US202063049522P 2020-07-08 2020-07-08
US63/049,522 2020-07-08
PCT/US2021/016666 WO2021158823A1 (en) 2020-02-04 2021-02-04 Methods for the treatment of scleroderma and related conditions

Publications (2)

Publication Number Publication Date
JP2023515771A JP2023515771A (ja) 2023-04-14
JP2023515771A5 true JP2023515771A5 (enExample) 2024-02-15

Family

ID=77200418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022547943A Pending JP2023515771A (ja) 2020-02-04 2021-02-04 強皮症および関連する疾病の処置のための方法

Country Status (11)

Country Link
US (2) US20210253686A1 (enExample)
EP (1) EP4100127A4 (enExample)
JP (1) JP2023515771A (enExample)
KR (1) KR20220151619A (enExample)
CN (1) CN115397518A (enExample)
AU (1) AU2021217378A1 (enExample)
BR (1) BR112022015447A2 (enExample)
CA (1) CA3169994A1 (enExample)
IL (1) IL295372A (enExample)
MX (1) MX2022009628A (enExample)
WO (1) WO2021158823A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025519600A (ja) * 2022-06-10 2025-06-26 アセリリン， インコーポレイテッド 抗ｉｇｆ－１ｒ抗体組成物
KR20250048156A (ko) * 2022-06-29 2025-04-07 리룸 테라퓨틱스, 인크. 제제에 접합된 인슐린 유사 성장 인자 1 수용체 리간드를 사용한 자가면역 질환의 치료
WO2025007015A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for multiple sclerosis
WO2025007012A2 (en) * 2023-06-30 2025-01-02 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for rheumatoid arthritis
CN119548621A (zh) * 2023-09-01 2025-03-04 苏州普乐康医药科技有限公司 抗igf-1r抗体或其抗原结合部分在减重中的应用
WO2025155894A1 (en) * 2024-01-19 2025-07-24 Sling Therapeutics, Inc. Use of inhibitors of insulin-like growth factor receptor-1 for fibrotic diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596854A4 (en) * 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2008144720A2 (en) * 2007-05-21 2008-11-27 University Of Washington Inhibitors of igf-1r signaling for the treatment of respiratory disorders
WO2010028274A1 (en) * 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
JP2012505900A (ja) * 2008-10-14 2012-03-08 ダイアクス コーポレーション 全身性強皮症に伴う肺線維症の治療および予防のためのｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質の使用
EP2785382B1 (en) * 2011-12-02 2019-01-02 IBC Pharmaceuticals, Inc. Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
EP2647994A1 (en) * 2012-04-03 2013-10-09 Universitätsklinikum Freiburg Method for diagnosis of pulmonary involvement in systemic sclerosis
CN107982247A (zh) * 2018-01-23 2018-05-04 中日友好医院 二甲双胍在制备治疗肺纤维化药物中的应用
EP3752161A4 (en) * 2018-02-15 2021-12-22 Children's Hospital Medical Center METHOD OF TREATMENT OF FIBROSE

Similar Documents

Publication Publication Date Title
JP5918275B2 (ja) 変形性関節症及び疼痛の治療
JP2020508303A5 (enExample)
JP2022548783A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2013500940A5 (enExample)
JP2020537644A5 (enExample)
RU2019118359A (ru) Антитело к cd73 человека
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
CN105358175B (zh) 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法
JP2023071956A5 (enExample)
JP2021514973A5 (enExample)
RU2015141418A (ru) Антитела, связывающие il-4 и/или il-13, и их применение
JP2013500941A5 (enExample)
JP2022549087A5 (enExample)
RU2009120052A (ru) Композиции и способы связывания сфингозин-1-фосфата
JP2025032102A5 (enExample)
NZ585559A (en) Humanized antibodies against tl1a
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
PE20160653A1 (es) Proteinas de union a il-17
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
JP2021501579A5 (enExample)
RU2019127870A (ru) Антитела против триптазы, их композиции и применения
JP2016503293A5 (enExample)
US20150203592A1 (en) Compositions and methods for treating osteoarthritis
JPWO2020059847A5 (enExample)